Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock Price

IKTStock

$1.65+9.27%52W

Market Cap$230.23M

P/E—

PEG Ratio—

Div yield—

Beta0.94

IKT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-12.85%

Price vs S&P 500 (4W)-23.67%

VGM Score36.99

Book Value / Share (Quarterly)$1.16

P/TBV (Annual)0.26x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.32

Price vs S&P 500 (YTD)-31.44%

Net Profit Margin (TTM)-5981.25%

EPS (TTM)$-0.50

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$-0.50

EPS (Annual)$-1.16

ROI (Annual)-29.01%

Net Profit Margin (5Y Avg)-4748.27%

Cash / Share (Quarterly)$1.20

ROA (Last FY)-27.91%

EBITD / Share (TTM)$-0.53

ROE (5Y Avg)-71.16%

Operating Margin (TTM)-6253.12%

Cash Flow / Share (Annual)$-0.21

P/B Ratio1.50x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$-786,300

EV / Revenue (TTM)621.96x

Net Interest Coverage (TTM)-738.50x

ROA (TTM)-43.48%

EPS Incl Extra (Annual)$-1.16

Current Ratio (Annual)21.70x

Quick Ratio (Quarterly)15.50x

3-Month Avg Trading Volume0.72M

52-Week Price Return9.27%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)883.82x

Asset Turnover (Annual)0.02x

52-Week High$2.61

Operating Margin (5Y Avg)-4841.72%

EPS Excl Extra (Annual)$-1.16

26-Week Price Return-2.94%

Quick Ratio (Annual)21.54x

13-Week Price Return-21.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.82x

Enterprise Value$199.03M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-25.76%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7304.75%

Cash / Share (Annual)$1.36

3-Month Return Std Dev55.13%

Net Income / Employee (TTM)$-1,378,800

ROE (Last FY)-29.01%

Net Interest Coverage (Annual)-178.00x

EPS Basic Excl Extra (Annual)$-1.16

P/FCF (TTM)2877.93x

Receivables Turnover (TTM)6.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)13.03x

ROI (TTM)-46.90%

P/S Ratio (TTM)719.48x

Pretax Margin (5Y Avg)-4748.27%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.00

Price vs S&P 500 (52W)-6.26%

Year-to-Date Return-19.51%

5-Day Price Return-10.57%

EPS Normalized (Annual)$-1.16

ROA (5Y Avg)-57.11%

Net Profit Margin (Annual)-7304.75%

Month-to-Date Return-19.71%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-1.20

Operating Margin (Annual)-7712.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-70.92%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)0.36x

P/B Ratio (Annual)1.44x

Pretax Margin (TTM)-5981.25%

Book Value / Share (Annual)$1.31

Price vs S&P 500 (13W)-24.49%

Beta0.94x

P/FCF (Annual)324.27x

Revenue / Share (TTM)$0.00

ROE (TTM)-46.90%

52-Week Low$1.33

vGradeF

mGradeC

vgmGradeD

IKT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.09	-$0.11	-17.86%(-$0.02)
Q4 2025	Mar 26, 2026	-$0.12	-$0.09	+23.94%(+$0.03)
Q3 2025	Nov 14, 2025	-$0.13	-$0.13	+0.00%(+$0.00)
Q2 2025	Aug 14, 2025	-$0.08	-$0.11	-37.50%(-$0.03)

IKT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.18

4.25

4.31

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IKTInhibikase Therapeutics, Inc. Common Stock	F	—	C	719.5x	—	—	—	$1.65
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Inhibikase Therapeutics, Inc. Common Stock

Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing selective protein kinase inhibitors for neurological disorders. Its lead program, Risvodetinib (IkT-148009), targets Parkinson's disease and related conditions driven by Abelson Tyrosine Kinase dysfunction. The company focuses on disease-modifying therapies for Parkinson's and other neurodegenerative conditions.